Fulvestrant
Information
- Drug Name
- Fulvestrant
- Description
- Entry(CIViC)
- 12
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02206984 | Active, not recruiting | Phase 2 | Endocrine Response in Women With Invasive Lobular Breast Cancer | September 30, 2015 | July 31, 2024 |
| NCT04603183 | Active, not recruiting | Phase 2 | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | June 2, 2021 | June 30, 2025 |
| NCT06047184 | Active, not recruiting | Phase 1 | Phase I Study of BEBT-209 in Women With Advanced Breast Cancer | July 15, 2019 | November 20, 2023 |
| NCT04579380 | Active, not recruiting | Phase 2 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | January 11, 2021 | May 31, 2025 |
| NCT05169567 | Active, not recruiting | Phase 3 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | March 11, 2022 | February 16, 2026 |
| NCT05759949 | Active, not recruiting | Phase 1 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | March 29, 2023 | July 25, 2024 |
| NCT04572295 | Active, not recruiting | Phase 1 | A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer | October 9, 2020 | December 31, 2024 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT04556773 | Active, not recruiting | Phase 1 | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | December 17, 2020 | November 28, 2025 |
| NCT04544189 | Active, not recruiting | Phase 2 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | January 20, 2021 | February 28, 2025 |
| NCT01560416 | Active, not recruiting | Phase 2 | Fulvestrant With or Without Ganetespib in HR+ Breast Cancer | May 2012 | December 2024 |
| NCT05176080 | Active, not recruiting | Phase 1/Phase 2 | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | December 8, 2021 | January 30, 2026 |
| NCT03393845 | Active, not recruiting | Phase 2 | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | January 29, 2018 | September 1, 2024 |
| NCT04524000 | Active, not recruiting | Phase 2 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | November 20, 2020 | January 31, 2025 |
| NCT04352777 | Active, not recruiting | Phase 2 | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | September 14, 2020 | December 30, 2024 |
| NCT01597388 | Active, not recruiting | Phase 1 | AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer | May 8, 2012 | September 5, 2028 |
| NCT03531645 | Active, not recruiting | Phase 2 | Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | August 13, 2019 | September 30, 2024 |
| NCT05090358 | Active, not recruiting | Phase 2 | Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer | October 8, 2021 | October 8, 2024 |
| NCT03854903 | Active, not recruiting | Phase 1 | WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor | April 1, 2019 | November 1, 2025 |
| NCT00585507 | Active, not recruiting | Phase 2 | Efficacy and Safety of 500mg of Fulvestrant | April 2004 | March 15, 2025 |
| NCT03179904 | Active, not recruiting | Phase 2 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | August 3, 2017 | July 30, 2024 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT03280563 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | December 26, 2017 | December 31, 2024 |
| NCT04305496 | Active, not recruiting | Phase 3 | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer | April 16, 2020 | June 7, 2024 |
| NCT03425838 | Active, not recruiting | Phase 3 | Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer | November 9, 2017 | December 2025 |
| NCT04300790 | Active, not recruiting | Phase 2 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | October 23, 2020 | June 30, 2026 |
| NCT01953588 | Active, not recruiting | Phase 3 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | December 13, 2013 | |
| NCT02632045 | Active, not recruiting | Phase 2 | Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer | March 2016 | June 10, 2024 |
| NCT05082025 | Active, not recruiting | Phase 2 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | September 27, 2022 | October 29, 2026 |
| NCT03633331 | Active, not recruiting | Phase 2 | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | August 15, 2018 | August 2024 |
| NCT01992952 | Active, not recruiting | Phase 1/Phase 2 | Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer | May 2014 | December 2023 |
| NCT05063786 | Active, not recruiting | Phase 3 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | September 14, 2021 | November 2024 |
| NCT03238196 | Active, not recruiting | Phase 1 | Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer | August 18, 2017 | September 25, 2024 |
| NCT02738866 | Active, not recruiting | Phase 2 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | October 25, 2016 | December 2024 |
| NCT05574881 | Active, not recruiting | Phase 1/Phase 2 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | September 1, 2022 | January 1, 2025 |
| NCT00099437 | Active, not recruiting | Phase 3 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | February 13, 2005 | March 29, 2024 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT02763566 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | December 5, 2016 | December 31, 2024 |
| NCT03772353 | Active, not recruiting | Phase 1/Phase 2 | Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer | May 12, 2019 | December 10, 2025 |
| NCT02792465 | Active, not recruiting | Phase 1 | A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors | November 11, 2016 | May 2027 |
| NCT03643510 | Active, not recruiting | Phase 2 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | August 21, 2018 | August 2026 |
| NCT02860000 | Active, not recruiting | Phase 2 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | July 6, 2017 | December 31, 2026 |
| NCT02107703 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer | July 22, 2014 | December 30, 2024 |
| NCT03781063 | Active, not recruiting | Phase 2 | Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | September 20, 2019 | December 2024 |
| NCT05433480 | Active, not recruiting | Phase 3 | A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer | May 25, 2022 | July 31, 2025 |
| NCT04224272 | Active, not recruiting | Phase 2 | A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer | June 10, 2020 | October 26, 2025 |
| NCT04214288 | Active, not recruiting | Phase 2 | A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer | April 22, 2020 | March 28, 2025 |
| NCT02947685 | Active, not recruiting | Phase 3 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | June 21, 2017 | July 31, 2026 |
| NCT02955394 | Active, not recruiting | Phase 2 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | September 21, 2017 | February 2027 |
| NCT04191499 | Active, not recruiting | Phase 2/Phase 3 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer | January 29, 2020 | September 30, 2030 |
| NCT04115306 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | November 14, 2019 | March 2026 |
| NCT03685331 | Active, not recruiting | Phase 1 | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | October 15, 2020 | April 2024 |
| NCT02983071 | Active, not recruiting | Phase 1/Phase 2 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | January 2017 | October 2023 |
| NCT04059484 | Active, not recruiting | Phase 2 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | October 22, 2019 | September 30, 2024 |
| NCT03006172 | Active, not recruiting | Phase 1 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | December 13, 2016 | November 30, 2024 |
| NCT01441947 | Active, not recruiting | Phase 2 | Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | October 2011 | December 2023 |
| NCT03056755 | Active, not recruiting | Phase 2 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments | August 14, 2017 | July 17, 2025 |
| NCT03099174 | Active, not recruiting | Phase 1 | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | May 4, 2017 | May 30, 2024 |
| NCT04053322 | Active, not recruiting | Phase 2 | Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | August 26, 2019 | August 2027 |
| NCT03147287 | Active, not recruiting | Phase 2 | Palbociclib After CDK and Endocrine Therapy (PACE) | September 5, 2017 | December 31, 2024 |
| NCT03959891 | Active, not recruiting | Phase 1 | AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | May 30, 2019 | December 2024 |
| NCT03939897 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | June 17, 2020 | March 11, 2025 |
| NCT04650581 | Active, not recruiting | Phase 3 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | January 27, 2021 | December 31, 2026 |
| NCT02028507 | Completed | Phase 3 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | March 13, 2014 | January 11, 2021 |
| NCT02049957 | Completed | Phase 2 | Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | February 13, 2014 | June 29, 2018 |
| NCT05054374 | Completed | Phase 1/Phase 2 | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | September 14, 2021 | October 26, 2023 |
| NCT02088684 | Completed | Phase 1 | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | May 19, 2014 | April 17, 2018 |
| NCT02116803 | Completed | Phase 2/Phase 3 | An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective | May 28, 2014 | November 28, 2016 |
| NCT02137083 | Completed | Phase 2 | A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer | April 2014 | July 2017 |
| NCT04707196 | Completed | Phase 4 | A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | February 22, 2021 | January 9, 2023 |
| NCT02219789 | Completed | Phase 1 | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | December 5, 2014 | October 1, 2018 |
| NCT02291913 | Completed | Phase 2 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | December 18, 2014 | January 31, 2019 |
| NCT02333370 | Completed | Phase 1 | A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | February 4, 2015 | September 29, 2022 |
| NCT02384239 | Completed | Phase 2 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | October 19, 2015 | January 31, 2021 |
| NCT04524728 | Completed | Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | December 2016 | June 2020 | |
| NCT02422615 | Completed | Phase 3 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. | June 9, 2015 | January 11, 2023 |
| NCT02437318 | Completed | Phase 3 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | July 23, 2015 | June 9, 2023 |
| NCT02447328 | Completed | Phase 4 | A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | May 29, 2015 | September 16, 2020 |
| NCT02491983 | Completed | Phase 2 | Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer | August 2015 | January 2020 |
| NCT02530424 | Completed | Phase 2 | "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " | May 2015 | November 2019 |
| NCT02536742 | Completed | Phase 2 | Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer | August 30, 2016 | December 22, 2022 |
| NCT02549430 | Completed | Phase 2 | To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | October 2012 | February 9, 2017 |
| NCT02599714 | Completed | Phase 1 | Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer | December 7, 2015 | November 23, 2023 |
| NCT02640755 | Completed | Phase 1 | Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | January 28, 2016 | July 6, 2017 |
| NCT02657343 | Completed | Phase 1/Phase 2 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | March 9, 2016 | June 30, 2022 |
| NCT02675231 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer | May 23, 2016 | November 9, 2023 |
| NCT02684032 | Completed | Phase 1 | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | June 14, 2016 | January 19, 2022 |
| NCT04258163 | Completed | Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | January 1, 2019 | July 1, 2019 | |
| NCT02756364 | Completed | Phase 2 | Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | July 28, 2016 | November 25, 2019 |
| NCT00012025 | Completed | Phase 2 | ICI 182780 in Treating Women With Metastatic Breast Cancer | May 2001 | August 2008 |
| NCT04256941 | Completed | Phase 2 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | May 31, 2019 | September 22, 2023 |
| NCT00057941 | Completed | Phase 2 | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer | September 2003 | June 2012 |
| NCT02795039 | Completed | Phase 1 | Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects | June 2016 | March 3, 2017 |
| NCT02894398 | Completed | Phase 2 | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | September 6, 2016 | February 15, 2023 |
| NCT04247126 | Completed | Phase 1 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | January 23, 2020 | March 30, 2023 |
| NCT02911844 | Completed | Phase 2 | Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension | April 10, 2017 | December 5, 2018 |
| NCT02970682 | Completed | Phase 2 | SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer | October 2016 | March 2019 |
| NCT03007979 | Completed | Phase 2 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | June 15, 2017 | March 31, 2023 |
| NCT03926936 | Completed | Phase 2 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study | March 13, 2019 | December 27, 2022 |
| NCT02392611 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | March 16, 2015 | October 11, 2017 |
| NCT00065325 | Completed | Phase 3 | The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer | August 2003 | September 2014 |
| NCT03439046 | Completed | Phase 3 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant | February 2, 2018 | December 11, 2023 |
| NCT00075764 | Completed | Phase 3 | S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | April 2004 | October 1, 2018 |
| NCT00082810 | Completed | Phase 2 | Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer | March 2004 | September 2008 |
| NCT00093002 | Completed | Phase 2 | Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer | June 2004 | July 2007 |
| NCT00100854 | Completed | Phase 2 | Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | October 28, 2004 | September 5, 2018 |
| NCT00146601 | Completed | Phase 2 | Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer | June 2004 | July 2007 |
| NCT00201864 | Completed | Phase 2 | Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer | September 2005 | February 2014 |
| NCT00241449 | Completed | Phase 3 | A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer | November 1998 | January 2012 |
| NCT00244998 | Completed | Phase 2 | Fulvestrant in Treating Patients With Advanced Prostate Cancer | September 2005 | June 2012 |
| NCT00256698 | Completed | Phase 3 | Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy | January 2004 | February 2012 |
| NCT00259090 | Completed | Phase 2 | Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer | April 2004 | October 2008 |
| NCT00272740 | Completed | Phase 2 | SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer | March 2000 | |
| NCT00274469 | Completed | Phase 2 | A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer | February 6, 2006 | January 13, 2017 |
| NCT00278915 | Completed | Phase 2 | Faslodex in McCune-Albright Syndrome | January 31, 2006 | July 20, 2023 |
| NCT00305448 | Completed | Phase 2 | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg | March 2006 | February 2012 |
| NCT00313170 | Completed | Phase 2 | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg | May 30, 2006 | March 13, 2019 |
| NCT00327769 | Completed | Phase 3 | Faslodex Advanced Breast Cancer Local Chinese Study | November 2005 | September 2007 |
| NCT00328120 | Completed | Phase 1 | Faslodex 500mg Multiple Dose Tolerability Study in BC Patients | April 2004 | June 2010 |
| NCT00334295 | Completed | Phase 2 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | December 2002 | January 2011 |
| NCT00357110 | Completed | Phase 2 | Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer | April 2006 | October 2008 |
| NCT00390455 | Completed | Phase 3 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | September 15, 2006 | July 2, 2014 |
| NCT00405938 | Completed | Phase 2 | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer | November 2006 | June 2011 |
| NCT00423917 | Completed | Phase 2 | Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer | August 2007 | January 15, 2017 |
| NCT00451555 | Completed | Phase 2 | Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer | April 11, 2007 | October 18, 2018 |
| NCT00454805 | Completed | Phase 2 | AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | March 2007 | April 2016 |
| NCT00476645 | Completed | Phase 2 | Fulvestrant in Hormone Refractory Prostate Cancer | September 2006 | December 2009 |
| NCT00534417 | Completed | Phase 2 | Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer | October 2007 | September 2011 |
| NCT00545077 | Completed | Phase 3 | Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women | November 6, 2007 | July 24, 2014 |
| NCT00570921 | Completed | Phase 2 | Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure | April 2008 | January 2015 |
| NCT00617188 | Completed | Phase 2 | Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | June 2007 | July 2008 |
| NCT00629616 | Completed | Phase 2 | Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer | October 2007 | April 2018 |
| NCT00635713 | Completed | Phase 3 | Second Line Breast Cancer Trial | May 1997 | September 2004 |
| NCT00660803 | Completed | Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer | May 2008 | April 2009 | |
| NCT00728949 | Completed | Phase 2 | A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | August 2008 | February 2015 |
| NCT00754325 | Completed | Phase 2 | Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor | September 2008 | January 2014 |
| NCT00871858 | Completed | Phase 2 | Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer | March 18, 2008 | July 2, 2018 |
| NCT05384119 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | January 9, 2023 | April 25, 2024 |
| NCT00921115 | Completed | Phase 2 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | May 2009 | March 20, 2023 |
| NCT00944918 | Completed | Phase 3 | Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) | December 2008 | June 2011 |
| NCT01142401 | Completed | Phase 2 | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | May 26, 2010 | January 8, 2021 |
| NCT01160718 | Completed | Phase 2 | Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy | August 2010 | September 2016 |
| NCT01186796 | Completed | Phase 1 | Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women | June 2009 | June 2013 |
| NCT01202591 | Completed | Phase 1/Phase 2 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | December 2010 | October 2014 |
| NCT01219699 | Completed | Phase 1 | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | October 5, 2010 | April 16, 2020 |
| NCT01296555 | Completed | Phase 1 | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | March 16, 2011 | June 25, 2021 |
| NCT01300351 | Completed | Phase 3 | Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | March 2011 | March 2014 |
| NCT01339442 | Completed | Phase 1 | BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer | November 14, 2011 | December 28, 2016 |
| NCT01344031 | Completed | Phase 1 | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | April 21, 2011 | |
| NCT01394016 | Completed | Phase 1 | A Phase 1 Study of LY2835219 In Participants With Advanced Cancer | December 7, 2009 | April 12, 2022 |
| NCT01399086 | Completed | Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer | April 2011 | September 2011 | |
| NCT01437566 | Completed | Phase 2 | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy | October 2011 | April 2016 |
| NCT01509625 | Completed | Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | January 2012 | March 2014 | |
| NCT01556191 | Completed | Phase 2 | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR | May 15, 2012 | June 17, 2020 |
| NCT01597193 | Completed | Phase 1 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | April 30, 2012 | January 22, 2018 |
| NCT01610284 | Completed | Phase 3 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | August 7, 2012 | April 19, 2019 |
| NCT01655225 | Completed | Phase 1 | A Study of LY3023414 in Participants With Advanced Cancer | July 31, 2012 | February 2, 2022 |
| NCT01670877 | Completed | Phase 2 | Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | December 11, 2012 | March 11, 2021 |
| NCT01797120 | Completed | Phase 2 | Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | May 31, 2013 | September 12, 2017 |
| NCT01942135 | Completed | Phase 3 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | September 26, 2013 | September 28, 2022 |
| NCT01989780 | Completed | Phase 2 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | January 2014 | June 2019 |
| NCT02026973 | Completed | Phase 1 | Impact of Endogenous E2 on SSI and GH Rebound | March 2014 | November 2015 |
| NCT03767335 | Completed | Phase 1 | MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer | July 19, 2018 | February 23, 2024 |
| NCT03691493 | Completed | Phase 2 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | February 8, 2019 | October 13, 2022 |
| NCT03310541 | Completed | Phase 1 | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | October 11, 2017 | May 3, 2023 |
| NCT03555877 | Completed | Phase 2 | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | March 15, 2018 | July 21, 2022 |
| NCT03344536 | Completed | Phase 1/Phase 2 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | November 10, 2017 | August 12, 2021 |
| NCT03363893 | Completed | Phase 1/Phase 2 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | November 14, 2017 | December 15, 2022 |
| NCT05577923 | Not yet recruiting | Phase 2 | Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) | November 1, 2022 | March 1, 2026 |
| NCT05806671 | Not yet recruiting | Phase 2 | Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | May 2023 | December 2025 |
| NCT06179303 | Not yet recruiting | Phase 2 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | July 6, 2024 | June 1, 2026 |
| NCT06341283 | Not yet recruiting | A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer | June 1, 2024 | July 1, 2025 | |
| NCT04337658 | Not yet recruiting | Phase 3 | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | July 1, 2020 | April 30, 2026 |
| NCT06428396 | Not yet recruiting | Phase 2 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | June 26, 2024 | May 24, 2028 |
| NCT04999540 | Not yet recruiting | Phase 2 | Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer | November 1, 2021 | December 30, 2024 |
| NCT05536128 | Not yet recruiting | Phase 2 | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | December 31, 2022 | December 31, 2025 |
| NCT06380751 | Not yet recruiting | Phase 3 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | April 18, 2024 | July 18, 2030 |
| NCT06408168 | Not yet recruiting | Phase 2 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) | October 31, 2024 | December 31, 2027 |
| NCT05392608 | Recruiting | Phase 2 | SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) | June 2, 2022 | March 2028 |
| NCT02476786 | Recruiting | Phase 2 | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | January 17, 2017 | January 31, 2030 |
| NCT02760030 | Recruiting | Phase 2 | Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | February 16, 2017 | December 31, 2024 |
| NCT02778685 | Recruiting | Phase 2 | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | September 30, 2016 | December 30, 2024 |
| NCT03424005 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | April 2, 2018 | May 3, 2026 |
| NCT04092673 | Recruiting | Phase 1/Phase 2 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | October 25, 2019 | March 31, 2025 |
| NCT04263298 | Recruiting | Phase 3 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | May 1, 2018 | May 1, 2030 |
| NCT04282031 | Recruiting | Phase 1/Phase 2 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | June 15, 2020 | March 15, 2024 |
| NCT04557449 | Recruiting | Phase 1/Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | September 23, 2020 | May 4, 2028 |
| NCT04567420 | Recruiting | Phase 2 | DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer | February 9, 2021 | December 15, 2026 |
| NCT04606446 | Recruiting | Phase 1 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors | November 16, 2020 | November 8, 2026 |
| NCT04762979 | Recruiting | Phase 2 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | February 12, 2021 | January 2025 |
| NCT04862663 | Recruiting | Phase 3 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | May 10, 2021 | August 14, 2029 |
| NCT04967248 | Recruiting | A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting | June 21, 2023 | December 19, 2025 | |
| NCT04975308 | Recruiting | Phase 3 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | October 4, 2021 | August 31, 2027 |
| NCT05038735 | Recruiting | Phase 3 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | November 29, 2021 | August 23, 2027 |
| NCT05076695 | Recruiting | Phase 2 | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer | October 15, 2021 | October 15, 2024 |
| NCT05101564 | Recruiting | Phase 2 | Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | March 20, 2023 | December 2026 |
| NCT05113368 | Recruiting | Phase 2 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | June 28, 2022 | December 1, 2024 |
| NCT05161195 | Recruiting | Phase 4 | Roll-over Study to Allow Continued Access to Ribociclib | July 7, 2022 | March 26, 2030 |
| NCT05181033 | Recruiting | Phase 2 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | December 27, 2021 | August 2025 |
| NCT05216432 | Recruiting | Phase 1 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | December 8, 2021 | August 31, 2026 |
| NCT05226871 | Recruiting | Phase 2 | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | July 7, 2022 | April 19, 2026 |
| NCT05230810 | Recruiting | Phase 1/Phase 2 | Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | August 25, 2022 | June 30, 2025 |
| NCT05251714 | Recruiting | Phase 1/Phase 2 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | May 27, 2022 | August 2025 |
| NCT05252416 | Recruiting | Phase 1/Phase 2 | (VELA) Study of BLU-222 in Advanced Solid Tumors | April 7, 2022 | September 30, 2026 |
| NCT05306340 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | August 3, 2022 | March 31, 2026 |
| NCT05307705 | Recruiting | Phase 1 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | May 11, 2022 | May 2025 |
| NCT05319873 | Recruiting | Phase 1/Phase 2 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | April 7, 2022 | April 1, 2026 |
| NCT05328440 | Recruiting | Phase 2 | Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | May 20, 2022 | January 1, 2026 |
| NCT05467891 | Recruiting | Phase 2 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | September 13, 2022 | December 2027 |
| NCT05501886 | Recruiting | Phase 3 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | September 30, 2022 | September 30, 2026 |
| NCT05524584 | Recruiting | Phase 2 | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | August 31, 2022 | December 31, 2028 |
| NCT05554354 | Recruiting | Phase 2 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | August 27, 2024 | November 1, 2026 |
| NCT05564377 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | April 7, 2023 | July 1, 2030 |
| NCT05601440 | Recruiting | Phase 2 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | June 13, 2023 | June 30, 2028 |
| NCT05608252 | Recruiting | Phase 1/Phase 2 | VS-6766+Abema+Fulv in Met HR+/HER- BC | February 23, 2023 | December 31, 2028 |
| NCT05631795 | Recruiting | Phase 4 | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment | August 9, 2022 | November 3, 2025 |
| NCT05646862 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | June 7, 2023 | March 30, 2029 |
| NCT05654623 | Recruiting | Phase 3 | A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. | March 3, 2023 | May 15, 2028 |
| NCT05720260 | Recruiting | Phase 2 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | January 17, 2023 | January 31, 2027 |
| NCT05768139 | Recruiting | Phase 1/Phase 2 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | April 17, 2023 | February 28, 2029 |
| NCT05867251 | Recruiting | Phase 1/Phase 2 | Study of AVZO-021 in Patients With Advanced Solid Tumors | August 30, 2023 | January 31, 2030 |
| NCT05870579 | Recruiting | Phase 1 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | November 13, 2023 | January 18, 2030 |
| NCT05933395 | Recruiting | Phase 2 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | October 10, 2023 | October 2031 |
| NCT05963984 | Recruiting | Phase 2 | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants | December 14, 2023 | June 16, 2025 |
| NCT06016738 | Recruiting | Phase 3 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | November 16, 2023 | September 30, 2027 |
| NCT06065748 | Recruiting | Phase 3 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | December 11, 2023 | December 30, 2028 |
| NCT06105632 | Recruiting | Phase 3 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | January 9, 2024 | December 14, 2028 |
| NCT06110793 | Recruiting | Phase 1/Phase 2 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | December 29, 2023 | November 2026 |
| NCT06120283 | Recruiting | Phase 1 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | December 1, 2023 | May 2026 |
| NCT06239467 | Recruiting | Phase 1 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | March 1, 2024 | August 1, 2027 |
| NCT06253195 | Recruiting | Phase 1 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | April 1, 2024 | October 26, 2026 |
| NCT06257264 | Recruiting | Phase 1 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | February 28, 2024 | December 31, 2026 |
| NCT06409390 | Recruiting | Early Phase 1 | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | April 26, 2024 | April 2027 |
| NCT04726332 | Terminated | Phase 1 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | February 10, 2021 | May 2, 2024 |
| NCT00183963 | Terminated | Phase 2 | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | August 2006 | June 2008 |
| NCT04862143 | Terminated | Phase 2 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant | March 8, 2022 | September 19, 2022 |
| NCT04899349 | Terminated | Phase 2 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | April 6, 2022 | May 10, 2023 |
| NCT00010153 | Terminated | Phase 3 | ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer | November 2000 | |
| NCT00903006 | Terminated | Phase 1/Phase 2 | Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | November 2009 | May 2013 |
| NCT01953926 | Terminated | Phase 2 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | September 30, 2013 | January 2, 2023 |
| NCT01633060 | Terminated | Phase 3 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | October 3, 2012 | September 21, 2017 |
| NCT00774878 | Terminated | Phase 2 | Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer | October 2008 | November 2010 |
| NCT00217464 | Terminated | Phase 2 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | June 2004 | March 2010 |
| NCT01528345 | Terminated | Phase 2 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | April 2012 | April 2015 |
| NCT00570258 | Terminated | Phase 2 | Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy | September 2006 | December 2017 |
| NCT03322215 | Terminated | Phase 2 | HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | October 24, 2017 | October 31, 2023 |
| NCT03584009 | Terminated | Phase 2 | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | September 6, 2018 | May 6, 2021 |
| NCT03294694 | Terminated | Phase 1 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | November 8, 2017 | October 14, 2020 |
| NCT03289039 | Terminated | Phase 2 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | October 25, 2017 | July 20, 2021 |
| NCT03241810 | Terminated | Phase 2 | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer | August 15, 2017 | November 30, 2018 |
| NCT03220178 | Terminated | Phase 4 | Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | July 24, 2017 | December 7, 2021 |
| NCT04031885 | Terminated | Phase 4 | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | August 14, 2019 | August 11, 2020 |
| NCT03134638 | Terminated | Phase 1 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | May 12, 2017 | June 24, 2020 |
| NCT02983604 | Terminated | Phase 1/Phase 2 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | January 10, 2017 | July 19, 2018 |
| NCT04060862 | Terminated | Phase 3 | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer | November 15, 2019 | August 29, 2023 |
| NCT00752986 | Terminated | Phase 2 | ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial | December 2008 | September 2013 |
| NCT02964507 | Terminated | Phase 1 | Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer | February 2, 2017 | July 19, 2021 |
| NCT02936206 | Terminated | Phase 1 | Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | October 2016 | May 1, 2020 |
| NCT02761694 | Terminated | Phase 1 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | June 26, 2016 | March 10, 2021 |
| NCT00372996 | Terminated | Phase 2 | Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer | February 2007 | June 2014 |
| NCT00543127 | Terminated | Phase 3 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | November 2007 | July 2016 |
| NCT02569801 | Terminated | Phase 2 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy | December 4, 2015 | February 28, 2020 |
| NCT04305236 | Terminated | Phase 2 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | July 23, 2020 | February 16, 2022 |
| NCT02540330 | Terminated | Phase 2 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant | March 2016 | August 13, 2020 |
| NCT02384746 | Terminated | Phase 1 | Phase I Study of the Combination of MLN9708 and Fulvestrant | June 2, 2015 | June 10, 2018 |
| NCT02374099 | Terminated | Phase 2 | Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | March 13, 2015 | November 21, 2017 |
| NCT00722072 | Terminated | Phase 2 | Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy | July 2008 | July 2012 |
| NCT02340221 | Terminated | Phase 3 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy | April 9, 2015 | June 29, 2021 |
| NCT02269670 | Terminated | Phase 2 | Phase II Study of Everolimus Beyond Progression | November 25, 2014 | January 25, 2021 |
| NCT02137837 | Terminated | Phase 3 | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | May 2014 | December 31, 2019 |
| NCT04738292 | Terminated | Phase 2 | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | October 5, 2021 | May 15, 2023 |
| NCT00927511 | Unknown status | Phase 2 | A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) | October 2008 | April 2012 |
| NCT02958852 | Unknown status | Phase 2 | A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer | November 2016 | April 2024 |
| NCT04856371 | Unknown status | Phase 1 | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | April 2021 | December 2022 |
| NCT03927456 | Unknown status | Phase 3 | A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | June 13, 2019 | December 30, 2022 |
| NCT00126464 | Unknown status | N/A | Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast | November 2004 | |
| NCT02913430 | Unknown status | Early Phase 1 | Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | April 24, 2018 | October 28, 2021 |
| NCT02909361 | Unknown status | Fulvestrant 500mg in Patients With Advanced Breast Cancer | October 11, 2017 | October 2022 | |
| NCT02394496 | Unknown status | Phase 3 | Overcoming Endocrine Resistance in Metastatic Breast Cancer | November 2007 | January 2017 |
| NCT02690480 | Unknown status | Phase 2 | Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | February 17, 2016 | December 2023 |
| NCT00688194 | Unknown status | Phase 3 | Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | May 2008 | |
| NCT03202862 | Unknown status | Phase 2 | The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer | July 1, 2017 | August 1, 2019 |
| NCT05000736 | Unknown status | Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC | September 1, 2021 | September 1, 2022 | |
| NCT02383030 | Unknown status | Phase 3 | Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients | November 2015 | December 2017 |
| NCT03182634 | Unknown status | Phase 2 | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | December 15, 2016 | November 2023 |
| NCT05047848 | Unknown status | N/A | Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer | August 18, 2021 | September 18, 2023 |
| NCT02072512 | Unknown status | Phase 2 | The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer | January 2014 | December 2016 |
| NCT02000193 | Unknown status | Phase 2 | Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer | November 2013 | December 2018 |
| NCT00006903 | Unknown status | Phase 2 | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer | August 30, 2004 | |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT04852081 | Unknown status | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | January 1, 2021 | December 1, 2021 | |
| NCT02216786 | Unknown status | Phase 2 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer | January 2014 | July 31, 2020 |
| NCT02530411 | Unknown status | Phase 2 | Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer | April 2015 | December 2020 |
| NCT05140655 | Unknown status | Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2- | April 19, 2021 | August 19, 2022 | |
| NCT00253422 | Unknown status | Phase 3 | Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | March 2004 | |
| NCT02404051 | Unknown status | Phase 3 | Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | December 2015 | January 2019 |
| NCT03803761 | Withdrawn | Phase 1/Phase 2 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | February 13, 2019 | February 19, 2022 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT04901299 | Withdrawn | Phase 2 | Fulvestrant + Neratinib In Breast Cancer | July 2023 | July 1, 2025 |
| NCT05905341 | Withdrawn | Phase 1 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | January 15, 2024 | April 13, 2028 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT02115594 | Withdrawn | Phase 2 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | April 2014 | June 2016 |
| NCT02140437 | Withdrawn | Phase 2 | Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | March 2014 | June 2016 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT05191004 | Withdrawn | Phase 1/Phase 2 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | September 2022 | September 2026 |
| NCT03377101 | Withdrawn | Phase 2 | Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer | August 7, 2018 | August 7, 2018 |
| NCT04498520 | Withdrawn | Phase 1 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | March 31, 2021 | June 30, 2025 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |